Q-omics provides the consensus-scored RN7SL851P profile across patient tissues and cancer cell-line models. RN7SL851P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RN7SL851P is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RN7SL851P RNA expression shows 10,033 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where RN7SL851P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL851P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL851P survival associations across molecular data types. RN7SL851P RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL851P RNA expression–survival associations across cancer types. High RN7SL851P expression shows unfavorable associations in KIRC, UVM and MESO, but favorable associations in HNSC, LAML and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RN7SL851P RNA expression.
This table summarizes RN7SL851P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL851P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL851P shows lower tumor expression in THCA and higher tumor expression in KIRC, BLCA, LUAD, PRAD and HNSC. The KIRC box plot shows higher RN7SL851P RNA expression in tumor versus normal tissue (log2 FC = +0.077, t-test p = .008).
This table shows molecular features associated with RN7SL851P in patient tissues and cancer cell lines. In patient samples, RN7SL851P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
